Adjunct To Incisional Glaucoma Surgery — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for adjunct to incisional glaucoma surgery. 12 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
12
Active US patents
52/100
Avg vulnerability
—
Annual revenue covered

Originators in Adjunct To Incisional Glaucoma Surgery

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Kyowa Kirin Co., Ltd. 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating adjunct to incisional glaucoma surgery. Each bar = one year. Y-axis scaled to peak year (7 patents).

2
26
1
28
2
29
7
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mitozytrex
MITOMYCIN
 Kyowa Kirin Co., Ltd. 12 52 — 2026-07-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9040074 Mitozytrex method of use 64 2031-01-20
9950069 Mitozytrex method of use 64 2031-01-20
10039832 Mitozytrex method of use 64 2031-01-20
12440568 Mitozytrex method of use 64 2031-01-20
12268745 Mitozytrex method of use 64 2031-01-20
9539241 Mitozytrex method of use 58 2028-01-02
9649428 Mitozytrex method of use 51 2029-05-21
8186511 Mitozytrex formulation 48 2026-07-19
9205075 Mitozytrex formulation 43 2026-07-19
7806265 Mitozytrex formulation 43 2029-02-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9950069 Mitozytrex formulation 31 2031-01-20
9040074 Mitozytrex formulation 31 2031-01-20
7806265 Mitozytrex formulation 43 2029-02-01
9205075 Mitozytrex formulation 43 2026-07-19
8186511 Mitozytrex formulation 48 2026-07-19
9649428 Mitozytrex method of use 51 2029-05-21
9539241 Mitozytrex method of use 58 2028-01-02
12268745 Mitozytrex method of use 64 2031-01-20
9040074 Mitozytrex method of use 64 2031-01-20
12440568 Mitozytrex method of use 64 2031-01-20

Related